Facebook
Twitter
LinkedIn
Forward
At the Forefront of Care for Patients with Worsening Heart Failure: New and Emerging Treatment Options
Welcome to our webcast on worsening heart failure. Heart failure remains one of the most challenging conditions to manage, with worsening heart failure being a critical area where suboptimal outcomes persist. While foundational therapies such as beta-blockers, ACE inhibitors, mineralocorticoid receptor antagonists, and ARNIs remain integral to heart failure management, advances in our understanding of heart failure pathophysiology have opened the door to newer, innovative therapeutic options, such as SGLT-2i, sCG stimulators and SGLT1/2 inhibitors.
This webcast is designed to deliver expert perspectives through a dynamic combination of didactic presentations and interspersed discussions. Together, we will explore the burden of worsening heart failure, review current treatment approaches, and delve into the clinical application of current and newer therapies through a patient case.
Target Audience
The educational design of this activity addresses the needs of US-based primary care physicians, cardiologists, advanced practice providers, as well as nurse practitioners, nurses, and pharmacists.
Learning Objectives
After completing this activity, the participant should be better able to:
- List the burden, symptom presentation, and definitions of worsening HF
- Review the rationale, mechanism of action, and efficacy and safety of new and emerging therapies for worsening HF and how they fit in into the HF treatment landscape
- Develop individualized treatment regimens for patients with worsening HF according to current recommendations and therapeutic advances
Additional Information
| Attachment | Size |
|---|---|
 Downloadable Slides | 3.52 MB |
Ileana L. Piña, MD, MPH, FAHA, FACC, FHFSA
The Robert Stein Chair of Quality
Professor of Medicine
Thomas Jefferson University
Chief Quality Officer
Senior Staff Fellow: Medical Officer
FDA, CDRH
Stephen J. Greene, MD
Associate Professor
Duke University School of Medicine
Duke Clinical Research Institute
Javed Butler, MD MPH MBA
Senior Vice President, Baylor Scott and White Health
President, Baylor Scott and White Research Institute, Dallas, Texas
Maxwell A. and Gayle H. Clampitt Endowed Chair
Baylor Scott and White Health
Dallas, Texas
Distinguished Professor of Medicine, University of Mississippi
Jackson, Mississippi
ESTIMATED TIME TO COMPLETE ACTIVITY
1.25 hours
EDUCATIONAL GRANT SUPPORT
Supported by an independent medical educational grant from Merck.
JOINT PROVIDERSHIP STATEMENT
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Cardiometabolic Health Congress (CMHC). PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING EDUCATION
PACE designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NURSING CONTINUING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.25 contact hours. Pharmacotherapy contact hours for Advance Practice Registered Nurses will be designated on your certificate.
PHARMACY CONTINUING EDUCATION
PACE designates this continuing education activity for 1.25 contact hours (0.125 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - JA4008073-9999-24-141-H01-P. Type of activity: Application
For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.
METHOD OF PARTICIPATION & REQUEST FOR CREDIT
There are no registration fees for this activity. Participation in this self-study activity should be completed in approximately 1.25 hour(s). To successfully complete this activity and receive CE credit, learners must follow these steps during the period from January X, 2025 through January X, 2026.
- Review the objectives and disclosures
- Study the educational content
- Successfully complete activity post-test(s)
- Complete the activity evaluation
You must receive a test score of at least 75% and respond to all evaluation questions to receive a certificate. Upon completing, your certificate will be available for print. For questions about receiving certificates, please contact us at [email protected]. For additional information about the accreditation of this activity, please visit https://partnersed.com
DISCLOSURES
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.
Dr. Piña, faculty for this educational activity, discloses the following:
- Consultant: Boehringer Ingelheim
Dr. Greene, faculty for this educational activity, discloses the following:
- Consultant: AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Corteria, Corcept, CSI, Vifor, Lexicon, Novo Nordisk, Otsuka, Merck, Roche, PharmaIN, Tricog, Bristol Meyers Squibb, Lilly
- Speaker: Novo Nordisk, Lexicon, Bayer, AstraZeneca, Boehringer Ingelheim
- Researcher: Novartis, Sanofi, AstraZeneca, Merck
Dr. Butler, faculty for this educational activity, discloses the following:
- Consultant: Abbott, American Regent, Amgen, Applied Therapeutic, AskBio, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cardiac Dimension, Cardior, CSL Bearing, CVRx, Cytokinetics, Edwards, Element Science, Faraday, Foundry, Innolife, Impulse Dynamics, Imbria, Inventiva, Ionis, Lexicon, Lilly, LivaNova, Janssen, Medtronics, Merck, Occlutech, Owkin, Novartis, Novo Nordisk, Pfizer, Pharmacosmos, Pharmain, Pfizer, Prolaio, Regeneron, Renibus, Roche, Salamandra, Sanofi, SC Pharma, Secretome, Sequana, SQ Innovation, Tenex, Tricog, Ultromics, Vifor, and Zoll.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Available Credit
- 1.25 ACPE Pharmacy
- 1.25 AMA PRA Category 1 Credit™
- 1.25 ANCC
- 1.25 Participation
Required Hardware/software
A computer with an internet connection
Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.